320 related articles for article (PubMed ID: 34450259)
1. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
[TBL] [Abstract][Full Text] [Related]
2. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
[TBL] [Abstract][Full Text] [Related]
3. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
5. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
Scalera S; Ricciuti B; Mazzotta M; Calonaci N; Alessi JV; Cipriani L; Bon G; Messina B; Lamberti G; Di Federico A; Pecci F; Milite S; Krasniqi E; Barba M; Vici P; Vecchione A; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Buglioni S; Pescarmona E; Sharma B; Felt KD; Lindsay J; Rodig SJ; De Maria R; Caravagna G; Cappuzzo F; Ciliberto G; Awad MM; Maugeri-Saccà M
Ann Oncol; 2023 Mar; 34(3):275-288. PubMed ID: 36526124
[TBL] [Abstract][Full Text] [Related]
6. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract][Full Text] [Related]
7. KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?
Pelosi G
J Thorac Oncol; 2021 Dec; 16(12):1979-1983. PubMed ID: 34809800
[No Abstract] [Full Text] [Related]
8. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
Zavitsanou AM; Pillai R; Hao Y; Wu WL; Bartnicki E; Karakousi T; Rajalingam S; Herrera A; Karatza A; Rashidfarrokhi A; Solis S; Ciampricotti M; Yeaton AH; Ivanova E; Wohlhieter CA; Buus TB; Hayashi M; Karadal-Ferrena B; Pass HI; Poirier JT; Rudin CM; Wong KK; Moreira AL; Khanna KM; Tsirigos A; Papagiannakopoulos T; Koralov SB
Cell Rep; 2023 Nov; 42(11):113295. PubMed ID: 37889752
[TBL] [Abstract][Full Text] [Related]
9. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
Vokes NI; Chambers E; Nguyen T; Coolidge A; Lydon CA; Le X; Sholl L; Heymach JV; Nishino M; Van Allen EM; Jänne PA
J Thorac Oncol; 2022 Jun; 17(6):779-792. PubMed ID: 35331964
[TBL] [Abstract][Full Text] [Related]
10. Redox
Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
[TBL] [Abstract][Full Text] [Related]
11. Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment.
Cheng W; Xu B; Zhang H; Fang S
Thorac Cancer; 2021 Sep; 12(18):2458-2467. PubMed ID: 34328274
[TBL] [Abstract][Full Text] [Related]
12. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
13. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
[TBL] [Abstract][Full Text] [Related]
15. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.
Jin X; Zheng Y; Chen Z; Wang F; Bi G; Li M; Liang J; Sui Q; Bian Y; Hu Z; Qiao Y; Xu S
Cancer Med; 2021 Dec; 10(23):8673-8692. PubMed ID: 34617407
[TBL] [Abstract][Full Text] [Related]
17. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
[TBL] [Abstract][Full Text] [Related]
18. Machine learning reveals two heterogeneous subtypes to assist immune therapy based on lipid metabolism in lung adenocarcinoma.
Gu X; Wei S; Li Z; Xu H
Front Immunol; 2022; 13():1022149. PubMed ID: 36238302
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide analyses reveal the contribution of somatic variants to the immune landscape of multiple cancer types.
Bi W; Xu Z; Liu F; Xie Z; Liu H; Zhu X; Zhong W; Zhang P; Tang X
PLoS Genet; 2024 Jan; 20(1):e1011134. PubMed ID: 38241355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
